Received Feb 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | UNK | — |
The office mistakenly administered a 3rd dose of Bexsero January 8, 2025; This non-serious case was reported by a nurse via sales rep and described the occurrence of extra dose administered in a 18-year-old patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (a patient received two Bexsero doses (one month apart) in 2023) and Bexsero (a patient received two Bexsero doses (one month apart) in 2023). On 08-JAN-2025, the patient received the 3rd dose of Bexsero. On 08-JAN-2025, an unknown time after receiving Bexsero, the patient experienced extra dose administered (Verbatim: The office mistakenly administered a 3rd dose of Bexsero January 8, 2025). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-JAN-2025 Nurse reported that a patient received two Bexsero doses (one month apart) in 2023. The office mistakenly administered a 3rd dose of Bexsero January 8, 2025 which led to extra dose administered.